Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Lung Cancer (NSCLC)

NCT02580708 is registered in ClinicalTrials.gov with Clovis Oncology, Inc. as lead sponsor.

NCT NCT02580708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02580708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Lung Cancer (NSCLC)
Lead sponsor
Clovis Oncology, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
September 30, 2015
Completion date
June 27, 2016
Enrollment
7 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer